



Galectin Therapeutics Inc.  
Investor Relations Department  
4960 Peachtree Industrial Boulevard,  
Suite 240  
Norcross, GA 30071  
United States

Visit IR website [↗](#)  
Sign-up for email alerts [↗](#)

NASDAQ: GALT

Last Trade:	2.54
Trade Time:	3:59 PM ET Oct 23, 2017
Change:	-0.12 ↓ (4.511%)
Day Range	2.49 - 2.73
52-Week Range	0.49 - 3.68
Volume	283,392

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.


## Company Profile

# Corporate Profile

Galectin Therapeutics is a biotechnology company focused on discovery and development. We apply our leadership in galectin science and drug development to create new therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Drug candidates based on our unique carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function.

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of directly involved in... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Oct 20, 2017*

[Galectin Therapeutics to Present Clinical Data at The Liver Meeting® 2017 Demonstrating the Ability of Non-Invasive Test to Identify Clinically Significant Portal Hypertension in Patients with Compensated NASH Cirrhosis](#)

*Sep 25, 2017*

[Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Conference for NASH Summit Europe 2017](#)

*Sep 12, 2017*

[Galectin Therapeutics Receives Notice of Chinese Allowance to Grant a Key Patent for Composition of Matter for GR-MD-02](#)

## Financials [\[ View all \]](#)

[Second Quarter Financial Results](#)

*Mar 28, 2017*

[Annual Report \(10-K\)](#)

*Nov 10, 2016*

[Proxy Statement \(DEF 14A\)](#)

*Aug 14, 2017*

[Quarterly Report \(10-Q\)](#)

*May 15, 2017*

[Quarterly Report \(10-Q\)](#)

*Nov 8, 2016*

[Quarterly Report \(10-Q\)](#)